Fulcrum Therapeutics, Inc.

NASDAQ:FULC

Biotechnology

Healthcare
$3.75 +1.71%

+$0.06 today

Market cap
$286.43M
Beta
2.92
P/E (TTM)
-3.6
EPS (TTM)
-$1.00
52W Low $2.83High $15.74

Volume 1.31M

Average 1.78M

Returns on capital

Fulcrum Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-21.5%

avg -234.4%

ROIC

-23.8%

avg -201.9%

ROA

-20.4%

avg -93.5%

Analysis

ROA is currently the strongest return metric at -20.4% versus its period average of -93.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Alexander C. Sapir

Chief Executive Officer, President & DirectorUSD 1.2M59——

Alan A. Musso

CFO, Treasurer & Principal Accounting OfficerUSD 802.22K64170.00K0.31%

Curtis G. Oltmans

Chief Legal Officer, Head of External Affairs & Corporate SecretaryUSD 689.5K63——

Bobby Riehle

Head of Program Strategy & Vice President————

Danny Reinberg

Founder————

Michael R. Green

Founder————

Iain Fraser DPHIL

Senior Vice President of Early Development————

Rudolf Jaenisch

Founder————

Tsun-Huei Lee

Founder—62——

Bradley E. Bernstein

Founder————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Feb 2, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

6

$1.49M

Sells

9

$59.15M

Net Transaction Value

−$57.67M

Net selling

Most Active

TANG KEVIN

6 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jul 17, 26

TANG KEVIN

Indirect

Buy$179.3K
Jul 16, 26

TANG KEVIN

Indirect

Buy$415.3K
Jul 15, 26

TANG KEVIN

Indirect

Buy$382.3K
Jul 14, 26

TANG KEVIN

Indirect

Buy$271.9K
Jul 14, 26

TANG KEVIN

Indirect

Buy$191K
Jul 13, 26

TANG KEVIN

Indirect

Buy$45.9K
Jun 26, 26

Ezekowitz Alan

Direct

Sell$65.6K
Feb 2, 26

Gould Robert J

Direct

Sell$160.9K
Jan 2, 26

Gould Robert J

Direct

Sell$163.1K
Jan 2, 26

Gould Robert J

Direct

Sell$178.1K

1–10 of 15

Summary

Insiders reported 6 buys worth $1.49M and 9 sells worth $59.15M over the last 12 months. That adds up to net selling of $57.67M. TANG KEVIN was the most active insider with 6 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Fulcrum Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about FULC's management, answered from reported figures.

Who manages FULC?

Fulcrum Therapeutics, Inc. (FULC) lists 10 active executives. The top listed executive is Bobby Riehle, Head of Program Strategy & Vice President.

Are FULC insiders buying or selling?

Recent insider activity shows net buying of $46.24M.